Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality. - Wikidata - awgldk - TriplyDB

Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality.

Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality.

http://www.wikidata.org/entity/Q37016976

about

CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.A systematic review of active treatment options in patients with desmoid tumours Treatment and follow-up strategies in desmoid tumours: a practice guideline.Optimal therapy for desmoid tumors: current options and challenges for the future.Characteristics of cultured desmoid cells with different CTNNB1 mutation status.Simple resection of truncal desmoid tumors: A case series Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis.

P2860

Q33553463-24617D0D-4D7C-4A00-B166-8549F4B172E8 Q33982743-FEC2BC08-789C-47FA-86B7-9CFEC6AA5DCE Q33982758-0FD40D49-489A-4281-B210-BF920A64B61C Q34674007-3B977CB6-4C1C-4CDD-939E-076EAE88F235 Q36528428-B1E85514-2830-455E-A23F-3682D9C683E8 Q37107708-59CE5DAF-CE73-4785-9001-8787577D9B87 Q41557583-773A8F69-F198-4742-AE96-951D2718CA71

P2860

Transition of treatment for patients with extra-abdominal desmoid tumors: nagoya university modality.

http://www.wikidata.org/entity/Q37016976

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 February 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Transition of treatment for pa ...... s: nagoya university modality.

@en

Transition of treatment for pa ...... s: nagoya university modality.

@nl

type

label

Transition of treatment for pa ...... s: nagoya university modality.

@en

Transition of treatment for pa ...... s: nagoya university modality.

@nl

prefLabel

Transition of treatment for pa ...... s: nagoya university modality.

@en

Transition of treatment for pa ...... s: nagoya university modality.

@nl

P1433

Q37016976-4CC47AB9-54C5-4701-97AA-9B2407F28394

P1476

Q37016976-F18E961C-84AE-4A90-9BD3-6D3F6395C0F2

P2093

Q37016976-12C5E19B-9DBD-4E04-B072-376108E04F4A

Q37016976-52435913-DC70-4A72-9728-E6CBE2758899

Q37016976-5C1D4B02-D0C5-4D28-91E5-1F632C0E8FE9

Q37016976-A1C359E6-6E6C-4F44-A009-5FFF58F3CA20

Q37016976-FDF7E75A-AC31-4559-8710-782FD228E7C7

P2860

Q37016976-0198EF4C-EED2-46C4-A41D-DDE0D6AA6C21

Q37016976-087C525C-5E8E-4D59-8E67-D717D9569F18

Q37016976-0A68FA2B-CD27-4034-A803-07D85F8B7D33

Q37016976-0D55F6C2-F264-45D2-8FDF-A48A0CB0556E

Q37016976-24770FC1-0003-4479-BCE2-DD7486374E62

Q37016976-2BFFEC2B-D0F7-4D3D-97A2-2D93C11E72E5

Q37016976-432EAE74-22B4-4C90-9DB7-4D6661599AF0

Q37016976-44C22D14-94E0-4B4B-9C80-31D02CF8EACD

Q37016976-4C2ECCB1-C225-4A1D-AEB9-8F8A90C002F4

Q37016976-4D9A6605-3708-4BB0-B977-ED281F9653E9

P304

Q37016976-E55219A5-52CA-4DDB-83DB-DD4C79E9673C

P31

Q37016976-00C5E446-C40D-4298-B3A4-7E57627DDFE1

P356

Q37016976-9416FDE2-C674-420D-AF16-75455EA49FBF

P433

Q37016976-D0106551-8AE3-42A2-B565-D3436ED2F3DE

P478

Q37016976-C0F6C011-6AD4-41A7-A4C7-8E0EDD743110

P50

Q37016976-93E76420-7533-413E-B575-24E457962A75

P577

Q37016976-39FFEED0-553B-47A6-91AE-3A5284A9925F

P5875

Q37016976-A02BE14D-EECE-4D7A-8F18-AA1917917C0A

P698

Q37016976-79E26CC2-EF86-4571-BA8F-1D1E9113CE9C

P932

Q37016976-BF2DB288-0AD5-4C19-A139-9BAF161844EC

P356

P1433

P1476

Transition of treatment for pa ...... rs: nagoya university modality

@en

P2093

Eisuke Arai

http://www.w3.org/2001/XMLSchema#string

Hiroshi Urakawa

http://www.w3.org/2001/XMLSchema#string

Naoki Ishiguro

http://www.w3.org/2001/XMLSchema#string

Yoji Shido

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Nishida

http://www.w3.org/2001/XMLSchema#string

P2860

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas

Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy.

Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles.

Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation.

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

The enigma of desmoid tumors.

The pharmacological treatment of aggressive fibromatosis: a systematic review.

P304

88-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/CANCERS4010088

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Satoshi Tsukushi

P577

2012-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258430061

http://www.w3.org/2001/XMLSchema#string

P698

24213228

http://www.w3.org/2001/XMLSchema#string

P932

3712685

http://www.w3.org/2001/XMLSchema#string